• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Complicated Intra-Abdominal Infections - Pipeline Review, H1 2013 Product Image

Complicated Intra-Abdominal Infections - Pipeline Review, H1 2013

  • Published: March 2013
  • 56 pages
  • Global Markets Direct

Complicated Intra-Abdominal Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Complicated Intra-Abdominal Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Complicated Intra-Abdominal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Complicated Intra-Abdominal Infections. Complicated Intra-Abdominal Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Complicated Intra-Abdominal READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Complicated Intra-Abdominal Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Complicated Intra-Abdominal Infections 7
Complicated Intra-Abdominal Infections Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Complicated Intra-Abdominal Infections Therapeutics – Products under Development by Companies 14
Companies Involved in Complicated Intra-Abdominal Infections Therapeutics Development 15
Merck & Co., Inc. 15
Rib-X Pharmaceuticals, Inc. 16
Cubist Pharmaceuticals, Inc. 17
Forest Laboratories, Inc. 18
Paratek Pharmaceuticals, Inc. 19
Atox Bio Inc. 20
Tetraphase Pharmaceuticals Inc. 21
Complicated Intra-Abdominal Infections – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
omadacycline tosylate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
delafloxacin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
(ceftolozane + tazobactam) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
eravacycline - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
(ceftazidime + avibactam) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CXA-201 + [metronidazole] + [meropenem] - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MK-7655 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Complicated Intra-Abdominal Infections Therapeutics – Drug Profile Updates 43
Complicated Intra-Abdominal Infections Therapeutics – Discontinued Products 50
Complicated Intra-Abdominal Infections – Product Development Milestones 51
Featured News & Press Releases 51
Sep 12, 2012: Tetraphase Pharma Announces Positive Phase II Data For Eravacycline In Patients With Complicated Intra-Abdominal Infections 51
Sep 05, 2012: Tetraphase Pharma To Present New Clinical And Preclinical Research On Antibiotic Portfolio At ICAAC 2012 52
Dec 13, 2011: Cubist Announces First Patient Dosed In Pivotal Global Phase III Trial Of CXA-201 For Complicated Intra-Abdominal Infections 52
Jun 16, 2005: FDA Approves Tygacil, First-in-class Antibiotic 53
Jan 28, 2005: FDA Grants Tygacil (Tigecycline) NDA Priority Review Status 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
Number of Products Under Development for Complicated Intra-Abdominal Infections, H1 2013 7
Products under Development for Complicated Intra-Abdominal Infections – Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Merck & Co., Inc., H1 2013 15
Rib-X Pharmaceuticals, Inc., H1 2013 16
Cubist Pharmaceuticals, Inc., H1 2013 17
Forest Laboratories, Inc., H1 2013 18
Paratek Pharmaceuticals, Inc., H1 2013 19
Atox Bio Inc., H1 2013 20
Tetraphase Pharmaceuticals Inc., H1 2013 21
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 27
Complicated Intra-Abdominal Infections Therapeutics – Drug Profile Updates 43
Complicated Intra-Abdominal Infections Therapeutics – Discontinued Products 50

List of Figures
Number of Products under Development for Complicated Intra-Abdominal Infections, H1 2013 7
Products under Development for Complicated Intra-Abdominal Infections – Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Route of Administration, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Molecule Type, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 27

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos